.jpeg)
2026-03-17 06:58:36
MDS targeted drugs are not chemotherapy; they are precision treatments targeting specific molecular markers. This article details the mechanistic differences, the critical role of genetic testing, side effect comparisons, and personalized strategies for children, the elderly, and patients with comorbidities.
2026-03-17 02:50:08
Repotrectinib is a ROS1/NTRK targeted anticancer drug developed by Bristol-Myers Squibb, approved in China in 2024. This article details drug origin, pricing, supply channels, and eligible patient populations for comprehensive medication reference.
2026-03-16 07:12:44
Ceritinib is a common oral targeted medication for non-small cell lung cancer. This article details drug storage temperature, environmental requirements, expiration date identification, and abnormal condition handling for safe medication use.
2026-03-16 06:56:17
Selumetinib is an oral MEK inhibitor for treating Type 1 Neurofibromatosis (NF1). This article details drug mechanism, SPRINT clinical data, indications, dosage guidelines, and safety management.
2026-03-13 07:08:13
Enasidenib is the first approved oral IDH2 inhibitor, brand name Idhifa, designed for patients with relapsed or refractory acute myeloid leukemia carrying IDH2 mutations. This article details mechanism of action, indications, dosage and adverse reaction management.
2026-03-13 05:38:15
Anagrelide is an oral platelet production inhibitor for treating essential thrombocythemia. This article covers indications, recommended dosage, administration methods, efficacy monitoring and common side effects for safe medication use.
2026-03-12 07:35:33
RAS mutations account for approximately 30% of malignancies, but resistance limits clinical benefits. New research reveals sustained mTORC1 activity as a non-genetic driver of RAS inhibitor resistance. Farnesyltransferase inhibitor Dalifarnib (KO-2806) blocks mTORC1 activation via RHEB, achieving rapid durable tumor regression when combined with RAS inhibitors.
2026-03-12 07:23:51
ARID1A is a key subunit of the SWI/SNF chromatin remodeling complex, with mutations linked to various cancers. Recent research reveals ARID1A deficiency triggers viral mimicry, enhancing tumor immunogenicity and providing new immunotherapy targets.
2026-03-12 06:53:06
Alectinib is a second-generation ALK inhibitor for treating ALK-positive advanced non-small cell lung cancer. This article comprehensively analyzes its first and second-line treatment efficacy, brain metastasis control, resistance issues, and safety profile for patients and healthcare professionals.
2026-03-12 05:06:31
Mavacamten (brand name Maifantuo), the first oral cardiac myosin inhibitor, targets obstructive hypertrophic cardiomyopathy (HCM) by curbing excessive myocardial contraction. It improves left ventricular outflow tract (LVOT) obstruction via ATPase inhibition. This article details its mechanism, indications, dosing, monitoring, and long-term management, emphasizing personalized care.
2026-03-12 03:31:19
Remibrutinib (brand name Ruipoduo) is a highly selective Bruton's tyrosine kinase (BTK) inhibitor for chronic spontaneous urticaria. Clinical studies show good safety and tolerability, with common side effects including headache and gastrointestinal reactions. Infection prevention, hematological monitoring, and long-term follow-up are key.
2026-03-11 07:15:54
Repotrectinib, as a next-generation ROS1/NTRK tyrosine kinase inhibitor, has attracted significant attention regarding its generational classification. This article professionally analyzes Repotrectinib's generation positioning, core characteristics, and treatment sequence based on the development history of ROS1 inhibitors.
